1 / 4

Tirzepatide

As a combined agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, it enhances the body's natural ability to regulate blood sugar and decrease appetite. The synergy between these two pathways is crucial, as it not only aids in weight reduction but also improves glycemic control. Visit : https://pommiermedspa.com/semaglutide-and-tirzepatide/

Neal5
Download Presentation

Tirzepatide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tirzepatide: A New Era in Weight Management This presentation introduces Tirzepatide. It is a novel treatment developed by Eli Lilly. Tirzepatide is marketed as Mounjaro for diabetes. It is also known as Zepbound for weight loss. This medication holds promise for improving metabolic health.

  2. Tirzepatide vs. Semaglutide: Dual vs. Single Action Semaglutide Tirzepatide GLP-1 receptor agonist GLP-1 and GIP receptor agonist Semaglutide acts as a GLP-1 receptor agonist. Tirzepatide has a dual action. It activates both GLP-1 and GIP receptors. This unique mechanism may offer enhanced efficacy. GLP-1 enhances insulin secretion. GIP reduces appetite and increases satiety.

  3. Clinical Trial Data: Zepbound's Impact Average Weight Loss 20.9% (52 lbs) Significant Difference ≥5% Weight Reduction 91% N/A The SURMOUNT-1 trial studied Tirzepatide for weight loss. It involved obese and overweight adults. The trial achieved significant results. Participants experienced an average weight loss of 20.9%. 91% achieved ≥5% weight reduction.

  4. Contact Us Address Phone Email 13119 Elk Mountain Dr, Riverview, FL, United States, Florida +1 813-343-2860 manager@pommiermedspa.com

More Related